GENE ONLINE|News &
Opinion
Blog

Clostridium Difficile Infection
BARDA Exercises $23.8 Million to Support Phase 3 Trial of Vedanta’s Encouraging Microbiome Therapy
2021-10-07
R&D
BARDA Funds Development of Live Biotherapeutic Product Against C. difficile Infections
2020-10-05
Trials & Approvals Clostridium Difficile
Seres Therapeutics’ Microbiome Therapy for Recurrent C. difficile Infections, Shines in Phase 3
2020-08-12
LATEST
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Comparing ESG Regulations in the U.S., the U.K., and the EU
2023-03-21
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
2023-03-21
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
READ MORE
EVENT
2023-03-28
Reuters Events: Pharma USA 2023
Philadelphia, USA
2023-04-24
Cell & Gene Therapy Summit 2023
Brussels, Belgium
2023-04-28
Boston Chinese Investment Club 2023 Biotech Pitch Competition
Boston, USA
2023-11-16
3rd INTERNATIONAL CONFERENCE ON NUTRITION AND HEALTHCARE
Dubai, UAE
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2023 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top